Cellectar Biosciences Introduces Phospholipid Ether-Drug Conjugate (PDC) Platform for Targeted Delivery of Chemotherapeutics
August 21, 2015 at 08:30 AM EDT
Cellectar Biosciences, Inc. (NASDAQ: CLRB), an oncology-focused biotechnology company, recently introduced its Phospholipid ether-Drug ...